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Several studies have shown physiological functions of
interleukin (IL)-32, a novel cytokine. However, the role of
IL-32 in cancer development has not been reported. In this
study, we showed that IL-32c inhibited tumor growth in
IL-32c-overexpressing transgenic mice inoculated with
melanoma as well as colon tumor growth in xenograft
nude mice inoculated with IL-32c-transfected colon
cancer cells (SW620). The inhibitory effect of IL-32c on
tumor growth was associated with the inhibition
of constitutive activated nuclear transcription factor-jB
(NF-jB) and of signal transducer and activator of
transcription 3 (STAT3). The expression of antiapoptotic,
cell proliferation and tumor-promoting genes (bcl-2,
X-chromosome inhibitor of apoptosis protein (IAP),
cellular IAP and cellular FADD-like IL-1b-converting
enzyme-inhibitory protein, cyclin D), cyclin-dependent
kinase 4, cycolooxygenase-2 and inducible nitric oxide
synthase was decreased, whereas the expression of
apoptotic target genes (caspase-3 and -9, bax) increased.
In tumor, spleen and blood, the number of cytotoxic
CD8
þ T cells and CD57
þ natural killer cells and the
levels of IL-10 increased, but that of tumor necrosis
factor-a (TNF-a), IL-1b and IL-6 decreased. We also
found that forced overexpression of IL-32c inhibited colon
cancer cell (SW620 and HCT116) growth accompanied
with the inhibition of activated NF-jB and STAT3
in vitro. In addition, when IL-32c was knocked down by
small interfering RNA (siRNA) or neutralized with an
anti-IL-32c antibody, IL-32c-induced colon cancer
cell growth inhibition, the IL-32c-induced decrease of
TNF-a, IL-1 and IL-6 production, and the increase of
IL-10 production were abolished. However, siRNA of
NF-jB and STAT3 augmented IL-32c-induced colon
cancer cell growth inhibition. These ﬁndings indicate
signiﬁcant pathophysiological roles of IL-32c in cancer
development.
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Introduction
Interleukin-32 (IL-32) was cloned as a gene induced by
IL-18 and was formerly known as natural killer (NK)
cell transcript 4 (Dahl et al., 1992). IL-32 is produced by
mitogen-activated lymphocytes, interferon-g-activated
epithelial cells and IL-12-activated NK cells (Kim
et al., 2005). IL-32 has six splice variants, IL-32a, IL-
32b, IL-32g, IL-32d, IL-32e and IL-32z, but the
functional differences between these isoforms remain
unknown (Nold-Petry et al., 2009). IL-32 modulates the
generation of tumor necrosis factor-a (TNF-a), IL-1b,
IL-6, IL-10 and two C–X–C chemokine family members
involved in inﬂammatory and/or autoimmune diseases
(Dinarello and Kim, 2006; Kang et al., 2009). Although
there are several limitations in the studies describing
IL-32 pathophysiological functions, signiﬁcant roles of
IL-32 have been reported in the development of several
diseases, such as arthritis, psoriasis, ulcerative colitis
and Crohn’s disease, as well as chronic obstructive
pulmonary disease (Dinarello and Kim, 2006; Calabrese
et al., 2008). However, the cognate receptor for IL-32
has not yet been identiﬁed despite numerous investiga-
tions. The lack of an identiﬁed receptor as well as the
presence of multiple IL-32 isoforms is very uncommon
among cytokines (Kim et al., 2005; Nold-Petry et al.,
2009). It is also unusual that soluble IL-32 is barely
detectable in culture medium and that IL-32 is localized
in both the cytosol and the nucleus (Dinarello and Kim,
2006; Kang et al., 2009). Thus, there may be non-
canonical and/or cell-associated functions of IL-32
besides its canonical role as a soluble factor.
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www.nature.com/oncCytokines are involved in inﬂammatory and/or
immune disease-associated cancer development (Lin
and Karin, 2007). Cytokines that are released in
response to infection can affect tumor development in
different ways. IL-8, which induces motility in non-
hematopoietic tumor cells, directly modulates endothe-
lial cell proliferation and migration, thus promoting
angiogenesis (Fujimoto et al., 2002). Tumor histology
revealed the collapse of large blood vessels and
disorganized vessel formation in mice that were inocu-
lated with IL-8-transfected cancer cells (Araki et al.,
2007). IL-6 increases antiapoptotic activity and, conse-
quently, tumorigenic potency in basal cell carcinoma
(Jee et al., 2001). However, Hisada et al. (2004) have
reported that IL-27 potently induces tumor-speciﬁc
antitumor activity. IL-2-stimulated lymphocytes have
proven to be effective in destroying tumors (Groscurth
et al., 1990). IL-10 inhibits tumor growth and metastasis
in an animal model (Huang et al., 1996; Kundu and
Fulton, 1997), and it inhibits tumor metastasis through
an NK cell-dependent tumor killing mechanism (Zheng
et al., 1996). IL-10-deﬁcient transgenic mice are more
susceptible to inﬂammation-associated adenocarcinoma
(Westbrook et al., 2009). Moreover, a negative correla-
tion between the expression of IL-10 and human colon
cancer development has also been shown (Cacev et al.,
2008). A few recent, limited studies showed higher
expression or higher protein level of IL-32 in the human
lung (Sorrentino and Di Carlo, 2009), pancreas cancer
patient tissue (Nishida et al., 2009) and stomach patient
tissue (Seo et al., 2008) than in normal tissue or serum.
In cancer cell line studies, IL-32 causes apoptotic cell
death in a human leukemia cell (Marcondes et al., 2008)
and HeLa cell lines (Goda et al., 2006). IL-32 is also
involved in the cisplatin-induced apoptotic cell death of
HeLa cells (Zhang et al., 2009), but in pancreatic cancer
cells, IL-32 stimulates cancer cell growth (Nishida et al.,
2009). However, the exact roles and mechanisms of IL-
32 in cancer development in vivo have not been reported.
The signal transducer and activator of transcription
(STAT) family proteins, especially STAT3 and nuclear
transcription factor-kB (NF-kB), have been proposed to
be important in inﬂammatory and/or immune disease-
associated carcinogenesis (Lin and Karin, 2007). NF-kB
and STAT3 are markedly activated in inﬂammatory and
immune cells by cytokines and chemokines, including
IL-6, IL-12, IL-17 and IL-23, which could stimulate
tumor cell growth ( Lu et al., 2004; Lin and Karin, 2007;
Yu et al., 2009). Activated NF-kB and STAT3 stimulate
pro-survival, proliferative, antiapoptotic and pro-angio-
genic genes in cancer development (Bromberg et al.,
1999; Lee et al., 2009). Therefore, changes of cytokine
levels in immune cells as well as in tumor cells could
affect NF-kB and STAT3 activity, thus playing critical
roles in tumorigenesis. In this study, we investigated the
role and mechanisms of IL-32g in melanoma and colon
cancer development using IL-32g-transfected colon
cancer cells, xenograft nude mice inoculated with
IL-32g-transfected colon cancer cells and IL-32g-over-
expressing transgenic mice inoculated with melanoma,
and we investigated the involvement of STAT3 and
NF-kB pathways in the action of IL-32g during cancer
development.
Results
Generation of IL-32g transgenic mice, and expression of
IL-32g in the mice
To investigate the role of IL-32g in tumor growth
in vivo, we generated transgenic mice overexpressing
human IL-32g (hIL-32g). Before generating the IL-32g
transgenic mice, we conﬁrmed that the IL-32g cDNA
was properly translated into the IL-32 protein using
glutathione S-transferase-fused IL-32g protein expres-
sion in Escherichia coli. The glutathione S-transferase-
fused IL-32g protein was detected by western blotting
with an anti-IL-32-reactive monoclonal antibody,
KU32-52, as described elsewhere (Kim et al., 2008).
The IL-32g cDNA was subcloned into the mammalian
expression vector pCAGGS, and this construct was used
for IL-32g transgenic mice production (Figure 1a). The
nature of the IL-32g transgenic mice was conﬁrmed by
polymerase chain reaction (PCR) of mouse tail genomic
DNA using allele-speciﬁc primers (Figure 1b). A 1.4-kb
PCR product was ampliﬁed from the IL-32g transgenic
mice allele. Among the more than 20 resultant pups,
three mice were found to be positive in the genotyping
analysis. These three founder mice were each back-
crossed into the C57BL6/J background for eight
generations. The transgene was successfully transmitted
to 50% of the pups from each littermate as evaluated by
genotyping and western blotting. Reverse transcription
(RT)–PCR and western blotting revealed that hIL-32g
was ubiquitously expressed in various tissues and highly
expressed in the intestine, liver, thymus and heart,
whereas there was no expression of hIL-32g in the
tissues of non-transgenic mice (Figure 1c). The male/
female ratio was 50% for the IL-32g transgenic and
non-transgenic littermates. IL-32g transgenic mice were
viable, fertile and had no tissue or organ abnormalities.
IL-32 level in the sera of IL-32g transgenic mice
(approximately 1.6ng/ml) detected by enzyme-linked
immunosorbent assay method was increased in the wild-
type mice (Figure 1d).
Inhibition of tumor growth in IL-32g transgenic mice
The antitumor effects of IL-32g were investigated using
transgenic mice (n¼10) overexpressing IL-32g.A s
IL-32g was highly expressed in the intestine, and many
cytokines play important roles in colon and melanoma
cancer development, we were interested in studying the
effect of IL-32g on these cancers. Colon cancer cells
could not be transplanted into the IL-32g transgenic
mice (C57BL6/J background) owing to the immune
rejection response. B16 melanoma cells were inoculated
subcutaneously into transgenic mice and non-transgenic
mice (n¼10). Tumor growth was monitored for 26 days
as the inoculated melanoma cells grew rapidly. There
was a signiﬁcant difference in tumor growth between the
transgenic mice and non-transgenic mice. The tumor
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signiﬁcantly smaller than in those of the non-transgenic
mice determined on day 26 (volume: 4056.1±819.5
versus 7217.3±1243.3mm
3, Po0.05; tumor weight:
9.2±2.9 versus 4.8±0.9g, Po0.05) (Figure 2a). The
histological ﬁndings after hematoxylin and eosin stain-
ing indicated that the tumor tissues of the transgenic
mice, but not those of the non-transgenic mice,
contained large areas of necrosis. Immunohistochemi-
cally, high levels of cleaved caspase-3 and bax were
found more frequently in the transgenic mice than in the
non-transgenic mice. The expression levels of cell cycle
regulatory proteins, cyclin D and cyclin-dependent
kinase 4 (CDK4), proliferation makers, proliferating
cell nuclear antigen and Ki-67, as well as inﬂammatory
proteins, cyclooxygenase 2 (COX-2) and inducible nitric
oxide synthase (iNOS), were reduced in the transgenic
mice (Figure 2b). TdT-mediated dUTP nick-end label-
ing (assay) (TUNEL) staining revealed a higher
frequency of apoptotic cell death in the tumor tissues
of the transgenic mice than in those of the non-
transgenic mice (Figure 2c). Western blotting showed
the expression of IL-32g in the transgenic mice tissues,
but not in the non-transgenic mice tissues. In the
transgenic mice, the expression levels of cell cycle
regulatory proteins, cyclin D and CDK 4, and anti-
apoptotic proteins, bcl-2 and cellular FADD-like IL-1b-
converting enzyme-inhibitory protein (c-FLIPL), as well
as inﬂammatory proteins, COX-2 and iNOS, were
decreased, whereas the levels of the pro-apoptotic bax,
and cleaved caspase-3 and -9 were increased (Figure 2d).
Inhibition of tumor growth in BALB/c athymic nude mice
inoculated with IL-32g-transfected colon cancer cells
We investigated whether the inhibitory effects of IL-32g
on colon cancer cell growth could bring about tumor
regression in vivo. Vector- or IL-32g-transfected SW620
cells were inoculated subcutaneously into BALB/c
athymic nude mice (n¼10), and tumor growth and
weight were monitored for 38 days. Tumor growth was
gradually and time-dependently retarded in the mice
inoculated with colon cancer cells expressing IL-32g
compared with the mice exposed to the empty vector.
On day 38, when the ﬁnal volumes were recorded, the
tumor volume and tumor weight of the mice inoculated
with the IL-32g-expressing colon cancer cells were 48.7
and 75.3% of the corresponding values for the mice
inoculated with the vector-expressing colon cancer cells,
respectively (Figure 3a). Immunohistochemical analysis
of tumor sections, stained with hematoxylin and eosin,
and for proliferation antigens, proliferating cell nuclear
antigen and Ki-67, revealed greater inhibitory effects of
IL-32g on tumor cell growth. We also conﬁrmed that the
expression levels of apoptotic cell death regulatory
proteins, that is, cleaved caspase-3 and bax, were
increased, but inﬂammatory proteins, iNOS and COX-
2, were decreased in the mice tumor tissue that were
inoculated with colon cancer cells expressing IL-32g
(Figure 3b). Apoptotic cell death was signiﬁcantly
induced in the mice tumor tissues that were inoculated
with IL-32g-expressing colon cancer cells (Figure 3c).
Consistent with the immunohistochemical data, western
blot analysis showed that IL-32g increased the expres-
sion levels of cleaved caspase-3 and -9, and bax, whereas
it decreased the expression levels of cyclin D, CDK4,
bcl-2 and c-FLIPL, as well as iNOS and COX-2
(Figure 3d).
IL-32g overexpression inhibits colon cancer cell growth
through induction of apoptotic cell death in cultured cells
To further investigate whether the introduction of
IL-32g into cancer cells changes their growth in vitro,
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Figure 1 Generation of IL-32g transgenic mice and detection of IL-32g.( a) Scheme for IL-32g transgenic generation. (b) PCR
analysis was performed to analyze IL-32g gene expression, as described in Materials and methods. (c) RT–PCR and western blotting
analyses for IL-32g in the spleen, thymus, liver, lung, kidney, colon and brain tissues of IL-32g transgenic and non-transgenic mice.
(d) Detection of IL-32 in the sera of transgenic mice or non-transgenic mice. The results are expressed as mean±s.d. of three mice.
*Po0.05 compared with non-transgenic mice. A full colour version of this ﬁgure is available at the Oncogene journal online.
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Oncogenewe carried out cell counting and analyses of morpho-
logical changes in colon cancer cells transfected with or
without the IL-32g gene. IL-32g was marginally
expressed in colon cancer cells without the introduction
of IL-32g determined with PCR analysis. The expression
of IL-32g was found to be increased depending on the
amount of introduced IL-32g cDNA, and correlated
with the inhibition of colon cancer cell growth
(Figure 4a). Morphological observations revealed that
enforced expression of IL-32g caused a gradual reduc-
tion in cell size and the rounding of individual colon
cancer cells. The introduction of IL-32g resulted in the
inhibition of colon cancer cell growth in a time-
dependent manner, as compared with the cells trans-
fected with empty vector (Figure 4b). To conﬁrm further
the relationship between the introduction of IL-32g and
colon cancer cell growth inhibition, the anticancer drug
paclitaxel was added to cancer cells, and the levels of
growth inhibition were determined. In the presence of
paclitaxel (5nM), the growth inhibition caused by IL-32g
was augmented (Supplementary Figure 1A). We also
found that introduction of IL-32g inhibited the prostate,
liver and lung cancer cell growth (Supplementary Figure
1B). These results indicate that IL-32g inhibits the
growth of several cancer cells.
To determine whether apoptotic cell death contrib-
uted to the observed inhibitory effect of IL-32g on colon
cancer cell growth, we evaluated the changes in
chromatin morphology of the IL-32g-expressing colon
cancer cells using TUNEL staining. The introduction of
IL-32g increased the number of apoptotic (40,6-diami-
dino-2-phenylindole-stained TUNEL-positive) colon
cancer cells. The frequencies of apoptotic cell death
without and with the introduction of IL-32g were 10 and
62% in the SW620 cells, and 4 and 49% in the HCT116
cells, respectively (Figure 4c). To elucidate the relation-
ship between the induction of apoptotic cell death by IL-
32g and the expression of apoptotic cell death-related
genes, the expression of apoptotic cell death regulatory
proteins was investigated. In the IL-32g-overexpressing
colon cancer cells, the expression levels of pro-apoptotic
proteins, that is, cleaved caspase-3, -9 and poly-(ADP-
ribose) polymerase, were increased. However, the
expression levels of the antiapoptotic proteins, bcl-2,
inhibitor of apoptosis protein (IAP), X-chromosome
IAP (XIAP), c-FLIP, and of cell proliferation markers,
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Figure 2 Effect of IL-32g on tumor growth in IL-32g-overexpressing transgenic mice. (a) Tumor images, volumes and weights. The
results are expressed as mean±s.d. *Po0.05 compared with the non-transgenic mice. (b) Tumor sections were analyzed by
immunohistochemistry. (c) Apoptotic cells were examined by ﬂuorescence microscopy after TUNEL staining. (d) Tumor extracts were
analyzed by western blotting. Each image and band is representative of three independent experiments. The values on the right of
panels b and d are average percentages of vector control over three independent experiments.
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Oncogenefor example, cyclin D and CDK4, were decreased in the
colon cancer cells by IL-32g. Furthermore, IL-32g
reduced the expression of inﬂammatory marker pro-
teins, COX-2 and iNOS (Figure 4d).
Silencing endogenous expression of IL-32g abolishes
IL-32g-induced cell growth inhibition and apoptotic cell death
When the colon cancer cells were co-transfected with the
IL-32g gene and IL-32g-speciﬁc small interfering RNA
(siRNA), consistent with the reduced enforced expres-
sion of IL-32g (Figure 5a), the IL-32g transfection-
induced inhibition of cell growth was signiﬁcantly
abolished in the colon cancer cells (Figure 5a). We also
found that recombinant IL-32g protein inhibited colon
cancer cell growth (Figure 5b). However, IL-32 anti-
body abolished the inhibitory effect of IL-32g on colon
cancer cell growth in the IL-32g-protein-treated
(Figure 5b) or IL-32g-transfected colon cancer cells
(Figure 5c). Furthermore, the increase in apoptotic cell
number induced by IL-32g was diminished by transfec-
tion of the IL-32g-speciﬁc siRNA (Supplementary
Figure 1C) and by treatment of IL-32 antibody in
SW620 colon cancer cells (Supplementary Figure 1D).
IL-32g decreases NF-kB activity in tumor tissues
and in colon cancer cells
The activation of NF-kB plays a critical role in cancer
cell survival. To determine whether IL-32g inhibits the
activation of NF-kB in colon cancer and melanoma cells
as well as tumors, we determined the DNA-binding
activity of NF-kB by electromobility shift assay, and
translocation of p50 and p65 into the nucleus and IkBa
protein degradation by western blot and immunohisto-
chemical analysis. The DNA-binding activity of NF-kB,
and translocation of p50 and p65 into the nucleus and
IkBa protein degradation were signiﬁcantly decreased in
the tumor tissues of xenograft nude mice that were
inoculated with IL-32g-overexpressing colon cancer cells
and transgenic mice that expressed IL-32g (Figures 6a
and b). Immunohistochemical analysis of p50 and p65
conﬁrmed that the intensities of nuclear staining for p50
and p65 were decreased in the tumor tissues of nude and
transgenic mice that expressed IL-32g (Figure 6c). As
NF-kB is highly activated in colon cancer cells (Ban
et al., 2009), the DNA-binding activity of NF-kB was
measured after the introduction of the vector or IL-32g
into the colon cancer cells. The introduction of IL-32g
inhibited the constitutive DNA-binding activity in the
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Oncogenecolon cancer cells (Figure 6d). Moreover, IL-32g
prevented the translocation of p50 and p65 into the
nucleus through the inhibition of the phosphorylation of
IkB (Figure 6e). Confocal microscopy conﬁrmed that
the translocation of p50 and p65 into the nucleus was
decreased by IL-32g (Figure 6f). We also showed that
introduction of the other subtype of IL-32 also
decreased constitutively activated NF-kB in the SW620
colon cancer cells transfected with IL-32a,- b and -g
(Supplementary Figure 2A), and IL32-g transfection
also inhibited constitutive or TNF-a-induced NF-kBi n
other cancer cells such as the prostate (PC3), liver
(HepG2) and lung (NICH4610) (Supplementary Figure
2B). In addition, the treatment with recombinant IL-32g
protein inhibited the constitutive DNA-binding activity
in the SW620 cells (Supplementary Figure 2C). The
DNA-binding activity of NF-kB was conﬁrmed by the
competition and supershift assays (Supplementary
Figure 2D). We also found that recombinant IL-32g
protein decreased TNF-a-induced NF-kB transcrip-
tional activity (Supplementary Figure 2E). However,
treatment with siRNA of IL-32g abolished IL-32g-
induced p65 and p50 translocation (Supplementary
Figure 3). To further investigate the effect of NF-kB
inactivation on cancer cell growth, we analyzed the
growth patterns of colon cancer cells, where p50 or p65
were knocked down by speciﬁc siRNAs. The knock
down of p50 and p65 augmented the inhibitory effect of
IL-32g on colon cancer cell growth (Figure 6g). These
data indicate that inhibition of NF-kB is implicated in
IL-32g-induced cancer cell growth inhibition.
IL-32g decreases STAT3 activity in tumor tissues
and in colon cancer cells
STAT3 is also implicated in inﬂammatory-associated
carcinogenesis and in maintaining of the constitutive
activation of NF-kB in cancer cells (Lee et al., 2009;
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The results are expressed as mean±s.d. of three experiments with each experiment performed in triplicate. *Po0.05 compared with the
vector-transfected colon cancer cells. (d) Cells were transfected with the vector or the IL-32g for 24h. Cell extracts were analyzed by
western blotting. Each band is representative of three independent experiments.
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OncogeneYu et al., 2009). Thus, we investigated whether IL-32g
inhibits STAT3 activation in colon and melanoma
tumors as well as in colon cancer cells. Consistent with
the inhibitory effect on NF-kB activation, STAT3
phosphorylation was signiﬁcantly decreased in the
tumor tissues of nude and transgenic mice that
expressed IL-32g (Figures 7a and b). Co-translocation
of p65 and p-STAT3 into the nucleus was also decreased
in the tumor tissues of nude and transgenic mice that
expressed IL-32g (Figures 7c and d). IL-32g also
inhibited the activated STAT3 activity (phosphorylation
of STAT3) in the colon cancer cells (Figure 7e).
Confocal microscopy conﬁrmed that the translocation
of p-STAT3 into the nucleus, and colocalization of p-
STAT3 and p65 were decreased by IL-32g in colon
cancer cells (Figure 7f). To investigate further the
inhibitory effect of IL-32g on STAT3 activation on
colon cancer cell growth, we analyzed the growth
patterns of colon cancer cells, where STAT3 was
knocked down by speciﬁc siRNAs. The knock down
of STAT3 augmented the inhibitory effect of IL-32g on
colon cancer cell growth (Figure 7g). These data indicate
that inhibition of STAT3 is implicated in IL-32g-
induced NF-kB inactivation and cancer cell growth
inhibition.
IL-32g induces the activation of CD8
þ cytotoxic T cells
and NK cells in the blood, tumor and immune organ
tissues, and alters cytokine levels
To investigate whether the inhibition of colon cancer
growth by IL-32g is related to tumor-speciﬁc immune
responses, we analyzed the expression patterns of CD8
þ
(cytotoxic T cells) and CD57
þ (NK cells) in tumor and
immune tissues. Immunohistochemically, more CD8
þ T
and CD57
þ cells were detected in the tumor sections of
nude mice inoculated with colon cancer cells expressing
IL-32 (Figure 8a). By staining the tumor sections from
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Figure 5 Effect of silencing endogenous IL-32g expression on colon cancer cell growth. (a) Colon cancer cells were inoculated into 24-
well plates (5 10
4 cells per well) and co-transfected with the IL-32g plasmid (0.4mg per well) and the IL-32g-speciﬁc siRNA (siIL-32;
50–100nM) or anti-IL-32 (5 or 10mg/ml) for up to 72h. The expression of IL-32g was determined as described above. Thereafter, cell
growth was measured by direct counting after Trypan blue staining. siCON: non-targeting control siRNA. (b) Colon cancer cells were
treated with either recombinant IL-32g alone or with its antibody and cultured for 72h. (c) Colon cancer cells were inoculated into 24-
well plates (5 10
4 cells per well) and transfected with the IL-32g plasmid (0.4mg per well) with/without anti-IL-32 (5 or 10mg/ml) for
up to 72h. All results are expressed as mean±s.d. of three experiments with triplicate tests in each experiment.
#Po0.05 compared with
the colon cancer cells transfected with vector alone (a, c) or untreated control (b). *Po0.05 compared with the colon cancer cells
transfected with IL-32g alone (a, c) or with recombination IL-32g protein (b). A full colour version of this ﬁgure is available at the
Oncogene journal online.
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OncogeneIL-32g transgenic mice, we found that there were also a
signiﬁcant higher number of CD8
þ T cells in the tumor,
as well as an increase in the number of NK cells
(Figure 8b). To investigate further the differences in the
numbers of CD8
þ T cells and NK cells between the
control and IL-32g-expressing cells in immunity-related
organs, we analyzed the levels of CD8
þ (cytotoxic T
cells) and CD49
þ reactive cell (NK cells) numbers in
spleen and thymus tissues. With respect to the spleen,
the numbers of CD8
þ T cells were much higher in the
IL-32g transgenic mice than those in the non-transgenic
mice, whereas there was a slight higher number in the
xenograft nude mice inoculated with IL-32g-expressing
colon cancer cells (Figure 8c). Thymus sections of the
IL-32g transgenic mice also showed increased levels of
CD8
þ T cells and NK cells as compared with those of
the non-transgenic mice (Figure 8d). Moreover, ﬂuor-
escence-activated cell sorting (FACS) analysis also
showed that the CD8
þ T- and NK cell number as well
as total B and T cells in the tumor tissues was higher in
the blood of IL-32g transgenic mice compared with
those of the non-transgenic mice (Figure 8e). Similar
increase of CD8
þ T- and NK cell number was found in
the blood and spleen even though the total number of
T and B cells was not much different (Supplementary
Table 1). These data suggest that IL-32g induces
antitumor immunity by promoting the activation of
CD8
þ T cells and NK cells in both tumor and immune
organ tissues, which are potent cytotoxic effectors
for tumors.
To investigate whether IL-32g alters other cytokine
levels in tumor tissues and immune organ (spleen), and
thus effect on the cancer cell growth, NF-kB and STAT3
signal and activation of immune cells in the tumor and/
or immune organ, we analyzed cytokine levels in tumor
tissues by quantitative RT–PCR. The levels of the tumor
growth-prompting cytokines, TNF-a, IL-6 and IL-1b,
were signiﬁcantly decreased, whereas the level of IL-10,
a tumor growth-inhibiting cytokine, was signiﬁcantly
elevated in the tumor tissues of IL-32g transgenic mice
Vector IL-32γ
IL-32γ
IL-32γ IL-32γ
Vector
21%
4%
68%
86%
67%
83%
32%
67%
p50 (NE)
p65 (NE)
Histone H1
p-IκBα (CE)
IκBα (CE)
β-actin
β-actin
IL-32γ
Vector
p50
p65
Non-Tg Tg
p50
p65
IL-32γ
Non-Tg
SW620
SW620
43%
31%
53%
81%
DAPI
DAPI
DAPI + p50
DAPI + p50
DAPI + p65
DAPI + p65
(Scale bar : 20 μm)
(Scale bar : 100 μm)
p50
p50
p65
p65
83% p50 (NE)
#
# #
*
*
SW620
SW620
Vector
IL-32γ
Vector
HCT116
#
# #
*
*
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
c
o
n
t
r
o
l
)
120
100
80
60
40
20
0
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
o
f
 
c
o
n
t
r
o
l
)
120
100
80
60
40
20
0
IL-32γ -
-
-
-
+
-
-
-
-
+
-
-
-
-
+
-
+
-
+
-
-
-
-
-
-
+ +
+
-
-
-
-
+
-
-
-
-
+
-
-
-
-
+
-
+
-
+
-
-
-
-
-
-
++
+
siCON (50 nM)
si p50 (50 nM)
si p65 (50 nM)
IL-32γ
siCON (50 nM)
si p50 (50 nM)
si p65 (50 nM)
p65 (NE)
Histone H1
p-IκBα (CE)
IκBα (CE)
51%
47%
89%
HCT116
HCT116
HCT116
Vector
IL-32γ Vector IL-32γ Vector
Vector
Tg
Non-Tg Tg
NF-κB
NF-κB
Figure 6 Effect of IL-32g on NF-kB activation in tumor tissues and colon cancer cells. (a) The DNA-binding activity of NF-kB was
determined by electromobility shift assay in the nuclear extracts of the xenograft mouse or IL-32g transgenic mice tumor samples.
(b, c) Expression of p50 and p65 in nuclear extracts and IkB phosphorylation in the cytosol of murine tumors, as determined by
western blotting (b) and immunohistochemistry (c). Each image and band is representative of three independent experiments. (d) The
DNA-binding activity of NF-kB was investigated using electromobility shift assay in nuclear extracts of colon cancer cells that were
transfected by IL-32g.( e, f) Expression of p50 and p65 in nuclear extracts and IkB phosphorylation in the cytosol, as determined by
western blotting (e), and ﬂuorescence microscopy (f). (g) Colon cancer cells were co-transfected with the IL-32g and p50/p65 siRNA for
up to 72h. Cell growth was measured by direct counting of cells stained with Trypan blue. The results are expressed as mean±s.d. of
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#Po0.05 compared with the colon cancer cells transfected with vector.
*Po0.05 compared with the colon cancer cells transfected with IL-32g alone. The values on the left of panels b and e are average
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Oncogenethan those in the non-transgenic mice (Figure 8c).
Similar alteration of cytokine levels was found in the
xenograft nude mice tumor tissues (Supplementary
Figure 4A) as well as SW620 colon cancer cells
expressing IL-32g (Supplementary Figure 4B). However,
treatment with siRNA of IL-32g abolished IL-32g
transfection-induced alteration of cytokine levels
(Supplementary Figure 4C).
Discussion
In this study, using IL-32g, the most biological active
form of the IL-32s (Choi et al., 2009), we found that
tumor growth was inhibited in the xenograft BALB/C
athymic nude mice inoculated with IL-32g-overexpres-
sing colon cancer cells and in the IL-32g-overexpressing
transgenic mice inoculated with B16 melanoma cells.
The inhibitory effect of IL-32g on tumor growth was
associated with the inhibition of constitutively activated
NF-kB and STAT3. This antitumor activity was also
associated with decreased expression of antiapoptotic,
cell proliferation and tumor-promoting genes (cleaved
caspase-3 and -9, bax, cyclin D and CDK4, COX-2 and
iNOS), but with increased expression of their target
apoptotic genes (bcl-2, xIAP, cIAP and c-FLIPL). In
tumor, blood and immune tissues, the number of
cytotoxic CD8
þ T cells and CD57
þ NK cells and the
levels of IL-10 increased, but that of TNF-a,I L - 1 b and
IL-6 levels decreased. When IL-32g was knocked down
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Figure 7 Effect of IL-32g on STAT3 activation in tumor tissues and colon cancer cells. (a, b) Phosphorylation of STAT3 in whole
extracts of murine tumors, as determined by western blotting (a) and immunohistochemistry (b). (c, d) Cellular localization p-STAT3
(green) and p65 (red) in tumor tissues of xenograft mice (c) and IL-32g transgenic mice (d). Each image and band is representative of
three independent experiments. (e) Colon cancer cells were transfected with the vector or the IL-32g for 24h. Whole-cell extracts were
prepared and analyzed for phosphorylated STAT3 by western blotting. Each band is representative of three independent experiments.
(f) Cellular localization of p-STAT3 (green) and p65 (red) was observed by confocal microscopy after immunoﬂuorescence staining of
colon cancer cells transfected with IL-32g.( g) Colon cancer cells were co-transfected with the IL-32g and STAT3 siRNA for up to 72h.
Cell growth was measured by direct counting of cells stained with Trypan blue. The results are expressed as mean±s.d. of three
experiments with triplicate tests in each experiment.
#Po0.05 compared with the colon cancer cells transfected with vector. *Po0.05
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Oncogeneby siRNA IL-32, NF-kB or STAT3, or neutralized with
an anti-IL-32 antibody, the IL-32g-induced colon cancer
cell growth inhibition; IL-32g-induced decrease
of TNF-a, IL-1 and IL-6 production; and increase of
IL-10 production were abolished. These ﬁndings suggest
that IL-32g has an inhibitory inﬂuence on tumor
development.
However, the fundamental mechanisms underlying
these phenomena are not clear. Because of their abilities
to induce the expression of a large array of inﬂamma-
tory mediators and their roles as core transcription
factors in diverse immune responses, NF-kB and STAT
family signals have been recognized as major pathways
responsible for cytokine-associated cancer development
or antitumor immunity (Mantovani et al., 2008; Baud
and Karin, 2009). When the colon cancer cells or the
in vivo tumor tissues were overexpressed with IL-32g,
the expression of NF-kB target genes, especially
inﬂammatory and tumor development-associated genes,
such as iNOS and COX-2, and antiapoptosis genes,
Bcl-2, cIAP, xIAP and c-FLIPL, and the DNA-binding
activity of NF-kB, were signiﬁcantly inhibited, but the
expression of cell death NF-kB target genes, such as Bax
and caspase-3 and -9, was enhanced. In addition, p50
and p65 translocation into the nucleus and phosphor-
ylation of IkBa was also inhibited. The inhibitory effect
on NF-kB activity was also found in conjunction with
other subtypes of IL-32, such as a and b, and in other
cancer cell lines, such as the prostate, liver and lung
(data not shown). The colon cancer cell lines and human
tumor samples, as well as the nuclei of stromal
macrophages in sporadic adenomatous polyps, had
increased levels of NF-kB (Hardwick et al., 2001; Lind
et al., 2001), which is likely acting as a survival factor for
colon and melanoma cancer cell growth. Constitutively
activated NF-kB has been associated with several
aspects of tumorigenesis, including tumor cell growth,
antiapoptosis and tumor promotion in colon cancer
(Karin et al., 2002). Thus, the inhibitory effects on
NF-kB activity and on the expression of target proteins
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Figure 8 Effect of IL-32g on the inﬁltration of CD8
þ T cells and NK cells into tumor tissues and immune organ tissues and on
cytokine levels in tumor tissues. (a–d) Immunohistochemistry was used to determine the level of CD8
þ- and CD57-reactive cell number
in tumor sections and immunity-related organs, as described in Materials and methods. Shown are the expression patterns of CD8
þ
and CD57 in the tumor sections of nude mouse xenografts (a) and IL-32g transgenic mice (b), as well as in the spleens (c) and thymuses
(d) of IL-32g transgenic mice. The images shown are representative of three sections from each mouse (n¼3). Each image and band is
representative of three independent experiments. (e) Subpopulation of immune cells determined after FACS analysis, as described in
detail in Materials and methods. The values in each area are the average subpopulation of immune cells (NK cells and CD8
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Each image is representative of three independent experiments. (f) The levels of IL-10, TNF-a, IL-1b and IL-6 in the tumor tissues of
transgenic mice (n¼3) were measured using quantitative real-time PCR, as described in Materials and methods. *Po0.05 compared
with non-transgenic mice tumor tissues.
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Oncogeneare critical in the IL-32g-induced inhibition of tumor
growth. Although it remains to be investigated, it is
worth noting that NF-kB is activated or inactivated by
many cytokines. It has been reported that IL-6 induces
the activation of NF-kB in the intestinal epithelia,
resulting in the induction of intercellular adhesion
molecule 1 expression (Wang et al., 2003), increase of
cell cycle progression and suppression of apoptotic cell
death-leading, tumor promotion (Lin and Karin, 2007).
In contrast, IL-10 blocks NF-kB activity, causing
apoptotic cell death of cancer cells (Schottelius et al.,
1999), and it inhibits the production of proinﬂammatory
cytokines, such as TNF-a, IL-6, IL-1b and IL-12, which
are closely associated with tumor development (Lin and
Karin, 2007). We found that the levels of TNF-a, IL-1b
and IL-6 were signiﬁcantly reduced, but IL-10 expres-
sion increased in the tumor tissues of BALB/C athymic
nude mice inoculated with colon cancers expressing IL-
32g and of IL-32g-overexpressing transgenic mice
inoculated with B16 melanoma cells. In addition,
siRNA of IL-32g or a neutralization with anti-IL-32
antibody abolished the constitutive activity of NF-kB
(p50 and p65 translocation into the nucleus) accom-
panied with the abolishment of cell growth inhibition;
decreased TNF-a, IL-1b and IL-6 production; increased
IL-10 production; and the induction of apoptotic cell
death in cultured colon cancer cells. Moreover, siRNA
of p50 and p65 augmented IL-32g-induced colon cancer
cell growth inhibition. Very similar to this ﬁnding, it was
also found that associated with attenuated tissue
damage, IL-6 and TNF-a was lower, but IL-10 level
was higher in IL-32g-overexpressed transgenic mice
compared with those levels of wild-type mice having
dextran sodium sulfate-inﬂamed colitis (Choi et al.,
2010). Therefore, it is possible that the inhibition of the
NF-kBs i g n a lb yI L - 3 2 g could play important roles in the
inhibitory effect of IL-32g on colon cancer development
and reduced production of pro-inﬂammatory cytokines
(TNF-a,I L - 1 b and IL-6), but an increase in the
production of anti-inﬂammatory cytokine (IL-10) could
be critically involved in this tumor killing effect of IL-32g.
We also found that STAT3 activation was signiﬁ-
cantly reduced in the tumor tissues of xenograft BALB/
C athymic nude mice inoculated with IL-32g-over-
expressing colon cancer cells and in those of the
IL-32g-overexpressing transgenic mice inoculated with
B16 melanoma cells. Recently, the role of STAT3 and
NF-kB and their relationship in inﬂammatory and
cytokine-associated cancer development have been
studied frequently (Lee et al., 2009; Yu et al., 2009).
Activated nuclear STAT3 has been detected in many
forms of cancer, including breast, colon, gastric, lung,
head and neck, skin, prostate and others (Lee et al.,
2009). Activation of STAT3 in the tumor contributes to
the expression of pro-cancer inﬂammatory mediators
and growth factors, leading to increased tumor growth.
STAT3 also induces the expression of antiapoptotic
genes in tumors (Lee et al., 2009). Conversely, condi-
tional STAT3 ablation inhibited tumor development
and progression (Chan et al., 2004; Jenkins et al., 2005).
In addition to the inhibitory effect of IL-32g on cancer
cell growth and STAT3 activation, we found that knock
down of STAT3 with siRNA further augmented the IL-
32g-induced inhibition of colon cancer cell growth.
Therefore, it is also possible that inhibition of the
STAT3 signal by IL-32g could play important roles in
the inhibitory effect of IL-32g on cancer development
too. Activated STAT3 can increase NF-kB activity in
cancer, and persistent activation of NF-kB in tumors is
dependent on STAT3 activation (Lee et al., 2009). In
agreement with these ﬁndings, we also found that
STAT3 and NF-kB were co-activated in colon cancer
cells and tumor tissues, and the introduction of IL-32g
reduced the co-activation of STAT3 and NF-kB.
Functional interaction between NF-kB and STAT3
can occur as well. Many genes whose products play
important roles in tumor development are controlled by
NF-kB and STAT3, either synergistically or individually
(Bromberg et al., 1999; Bollrath and Greten 2009; Lee
et al., 2009; Grivennikov and Karin, 2010). The
expression of antiapoptotic genes, such Bcl-2, xIAP2
and cIAP2, which are prominent targets for NF-kBa n d
STAT3, was increased by IL-32g; however, the expres-
sion of NF-kB-dependent tumor-promoting genes,
such as c-FLIP, COX-2 and iNOS, was inhibited.
The expression of STAT3 and NF-kB target genes
controlling cell cycle and proliferation, such as cyclins D
and B (Levy and Darnell, 2002; Jenkins et al., 2005;
Naugler and Karin, 2008), also was decreased by
treatment with IL-32g, and it was accompanied with
G0/G1-phase cell cycle arrest. Thus, the blocking ability
of IL-32g on STAT3 alone and/or coordination of the
inhibitory effect on NF-kB could be signiﬁcantly
associated with the inhibition of tumor growth by IL-
32g. It remains to be determined how IL-32g inhibited
activated STAT3 and NF-kB, but it is also worth noting
that several cytokines can modulate STAT3 and NF-kB
activities to increase gene transcription. IL-6 activates
STAT3, whereas IL-10 inhibits the activation of STAT3
during tumor growth inhibition (Yu et al., 2009). The
acetylation and/or recruitment of p300 protein are
critical in cytokine-induced activation of STAT3 and
NF-kB, and this cytokine (IL-6) prolongs their retention
in the nucleus (Choi et al., 2002; Hou et al., 2008; Ray
et al., 2008; Ma et al., 2010). We found that acetylation
of p65 and expression of p300 in the nucleus of colon
cancer cells were inhibited by the introduction of IL-32g
and in the nucleus of tumor tissues overexpressing
IL-32g (data not shown). Thus, direct inhibition of
acetylation and/or recruitment of p300 protein may
partially contribute to the inhibitory effects of IL-32g on
the inactivation of STAT3 and NF-kB. Indirect
inactivation via modulation of other cytokines in the
tumor tissues (decreases of TNF-a, IL-6, and IL-1b and/
or an increase of IL-10) may also play a role in the
inhibitory effects of IL-32g on the inactivation of
STAT3 and NF-kB.
The interaction between tumor and immune cells is
primarily responsible for overall tumor progression (or
regression) and the spreading or induction of antitumor
immune responses and tumor rejection (Shurin et al.,
2006). Cytokines can act as inducers, causing the
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Oncogeneactivation of T cells (cytotoxic CD8
þ T cells) and NK
cells in the tumor tissues, which results in the apoptotic
cell death of tumor cells (Moretta et al., 2000). The
expression of IL-2 and IL-10 at the site of tumors
enhances tumor killing ability by inducing the genera-
tion of tumor-reactive cytotoxic T lymphocytes and by
allowing the increased inﬁltration of activated T cells
into the tumors (Lee et al., 1998). We found that IL-32g-
overexpressing transgenic mice and xenograft nude mice
have higher levels of CD8þ T cells and CD57-positive
NK cells in the tumor area, blood, spleen and thymus.
Thus, activation of immune cells, such as cytotoxic T
cells and NK cells, could be important in the inhibition
of colon cancer development by IL-32g. Several recent
studies have reported that activation of STAT3 and
NF-kB signals in tumors by cytokines, such as IL-6 and
IL-12, impedes dendrite maturation and inhibits the
generation of T cells, giving rise to immune tolerance
against cancers (Lee et al., 1998; Moretta et al., 2000;
Chan et al., 2004; Jenkins et al., 2005; Shurin et al.,
2006). Thus, it is possible that inactivation of STAT3
and NF-kB by the overexpression of IL-32g may also
enhance immune responses to the tumor via an increase
of trafﬁc into the tumor area or maturation of immune
cells, especially cytotoxic T cells and NK cells,
thereby causing indirect inhibition of tumor growth.
We are currently studying the roles and mechanisms of
IL-32s on the immune responses against cancer devel-
opment. The present data conclusively show that IL-32g
can act as a cytokine-inhibiting cancer cell growth
and that the inhibition of NF-kB and STAT3 signaling
and the reduced production of pro-inﬂammatory
cytokines (but increased production of anti-inﬂamma-
tory cytokines) play an important role in the inhibitory
effect of IL-32g on colon cancer and melanoma cell
growth.
Materials and methods
Generation of IL-32g transgenic mice
To generate transgenic mice that express hIL-32g, concen-
trated hIL-32g cDNA was prepared. The pCAGGS/hIL-32g
plasmid was prepared using the Qiagen MIDI-Prep Kit. To
generate IL-32g transgenic mice, a 705-base pair fragment of
the hIL-32g gene was subcloned into the EcoRI sites of the
pCAGGs expression vector. The sequence of the IL-32g insert
was conﬁrmed by automated sequencing. The IL-32g gene-
containing genomic fragment was released from the vector
using SalI/HindIII digestion, and then separated from the
pCAGGs vector using low-melting-point agarose and trans-
verse alternating ﬁeld-gel electrophoresis. The fragment was
puriﬁed and microinjected at a concentration of 4ng/ml into
the embryos of BDF1 mice, as described previously (Wang
et al., 2005; Kim et al., 2008). The experimental treatments
were carried out according to the guidelines for animal
experiments of the Faculty of Disease Animal Model Research
Center, Korea Research Institute of Bioscience and Biotech-
nology (Daejeon, Korea). IL-32g insertion was conﬁrmed by
ampliﬁcation of genomic DNA isolated from the transgenic
mice tails using Super Taq PLUS Pre-mix (RexGeneBioTech,
Seoul, Korea) and the following speciﬁc primer set: sense,
50-GAAGGTCCTCTCTGATGA
CA-30; and antisense, 50-GAAGAGGGACAGCTATGAC
TG-30 (nt 2245–2225). pCAGGS/IL-32g was used as a positive
control, and pCAGGS (4.8kb) was used as a negative control.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as an internal control. Genomic DNA samples were
extracted from transgenic mice tails and PCR analysis was
performed for IL-32g gene expression. The following condi-
tions were used for the TaKaRa PCR Thermal Cycler: 941C
for 10min, followed by 35 cycles of 941C for 1min, 631C for
1min and 721C for 1.5min, with a ﬁnal step of 721C for
10min. To analyze IL-32 gene expression in various tissues of
transgenic mice, total RNAs were extracted and RT–PCR
analysis was performed using primer sets as follows: sense,
50-GAAGGTCCTCTCTGATGACA-30; antisense, 50-GGGG
TTCAGAGCACTTCT-30 (371bp). GAPDH was used as an
internal control as follows: sense, 50-ACCACAGTCCATGC
CATCAC-30; antisense, 50-TCCACCACCCTGTTGCTGTA-30
(450bp). IL-32g protein expressed in the tissues of transgenic
mice was detected by western blotting with an anti-IL-32
monoclonal antibody KU32-52 (Kim et al., 2008).
Antitumor activity of IL-32g in IL-32g transgenic mice
Male, 6- to 8-week-old IL-32g transgenic and non-transgenic
mice were maintained in accordance with the guidelines
proscribed by the Chungbuk National University Animal
Care Committee (Chungbuk, Korea). B16 melanoma cells
were injected subcutaneously (5 10
5 tumor cells in 0.1ml
phosphate-buffered saline per animal) into transgenic mice and
non-transgenic mice. The weights and tumor volumes of the
animals were monitored twice weekly. The tumor volumes
were measured with Vernier calipers and calculated using the
following formula: (A B
2)/2, where A is the larger and B is
the smaller of the two dimensions. At the end of the
experiment, the animals were killed and the tumors were
separated from the surrounding muscles.
Detection of IL-32 in the sera of transgenic mouse
The level of IL-32 in the sera was detected by enzyme-linked
immunosorbent assay methods as described elsewhere (Lee
et al., 2010).
In vivo antitumor activity of IL-32g in a xenograft animal model
Six-week-old male BALB/c athymic nude mice were purchased
from Japan SLC (Hamamatsu, Japan). All experiments were
approved and carried out according to the Guide for the Care
and Use of Animals (Chungbuk National University Animal
Care Committee). Human colon cancer SW620 cells that had
been transfected with the vector or the IL-32g plasmid (6mg/
1 10
6 cells) were injected subcutaneously (1 10
7 tumor cells
in 0.1ml PBS per animal) into the right-lower ﬂanks of the
carrier mice. The body weights and tumor volumes of the
animals were monitored twice weekly. The formula described
above was used to calculate tumor volume. At the end of the
experiment, the animals were killed by cervical dislocation.
The tumors were separated from the surrounding muscles and
dermis, excised and weighed.
Immunohistochemistry
All specimens were ﬁxed in formalin and embedded in parafﬁn
for examination. Sections (4-mm thickness) were stained with
hematoxylin and eosin and analyzed by immunohistochem-
istry as described elsewhere (Son et al., 2007) using primary
mouse anti-human proliferating cell nuclear antigen, Ki-67,
bax (1:200 dilution), CD3 (1:10) and CD57 (1:50) monoclonal
antibodies or primary rabbit anti-human cleaved caspase-3
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mouse and anti-rabbit antibodies.
Detection of apoptosis
TUNEL assays were performed using the In situ Cell Death
Detection Kit (Roche Diagnostics GmbH, Mannheim, Ger-
many), as described elsewhere (Son et al., 2007). The total cell
number in a given area was determined based on 40,6-
diamidino-2-phenylindole nuclear staining. The apoptotic
index was calculated as the number of 40,6-diamidino-2-
phenylindole-stained, TUNEL-positive cells divided by the
total number of cells counted 100.
Reagents and cell culture
The HCT116 and SW620 colon cancer cell lines and B16
melanoma cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). Colon cancer
cells were grown at 371Ci n5 %C O 2 humidiﬁed air in
RPMI 1640 medium that contained 10% fetal bovine serum
(FBS), 100U/ml penicillin and 100mg/ml streptomycin. B16
melanoma cells were grown at same conditions in DMEM
medium. RPMI 1640, DMEM, penicillin, streptomycin
and FBS were purchased from Gibco Life Technologies
(Grand Island, NY, USA). siRNA species for IL-32, p50
and p65, and a non-targeting control siRNA were purchased
from Bioneer (Daejeon, Korea) and siRNA for STAT3
was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
Transfection
Colon cancer cells (5 10
4 cells per well) were plated in 24-well
plates and transiently transfected with 0.4mg of the empty
vector or the constitutively activated full-length IL-32g
plasmid per well, using a mixture of plasmid and the
WelFect-EX PLUS reagent in OPTI-MEN, according to the
manufacturer’s speciﬁcation (WelGENE, Seoul, Korea).
Cell viability
To determine viable cell numbers, the colon cancer cells were
seeded onto 24-well plates (5 10
4 cells per well). The cells
were trypsinized, pelleted by centrifugation for 5min at
1500r.p.m., resuspended in 10ml of PBS and 0.1ml of 0.2%
Trypan blue was added to the tumor cell suspension in each
solution (0.9ml each). Subsequently, a drop of suspension was
placed in a Neubauer chamber, and the living cancer cells were
counted. Cells that showed signs of Trypan blue uptake were
considered to be dead, whereas those that excluded Trypan
blue were considered to be viable. Each assay was carried out
in triplicate.
Western blotting
Western blot analysis was performed as described previously
(Son et al., 2007). The membranes were immunoblotted with
the following primary antibodies: mouse monoclonal anti-
bodies directed against p65, p50 and c-FLIP (1:500 dilutions;
Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal
antibodies directed against bax, poly-(ADP-ribose) polymer-
ase, COX-2, iNOS and CDK4 (1:500 dilutions; Santa Cruz
Biotechnology) and against caspase-3, cleaved caspase-3,
caspase-9, Bcl-2, XIAP, c-IAP-1 and Akt (1:1000 dilutions;
Cell Signaling Technology, Beverly, MA, USA). The mono-
clonal anti-hIL-32 antibody KU32-52 was used as reported
previously (Kim et al., 2008).
Gel electrophoretic mobility shift assay
A gel electromobility shift assay was performed according to
the manufacturer’s recommendations (Promega, Madison, WI,
USA), as described elsewhere (Son et al., 2007).
Fluorescence microscopy
The ﬁxed cells and tissues were exposed to following primary
antibodies: p50, p65 and p-STAT3 (1:100 dilutions in blocking
serum; Santa Cruz Biotechnology) at room temperature for
1h. After incubation, the cells were washed twice with ice-cold
PBS and incubated with an anti-rabbit or -mouse secondary
antibody conjugated to Alexa Fluor 488 or 568 (Invitrogen–
Molecular Probes, Carlsbad, CA, USA) at room temperature
for 1h. Immunoﬂuorescence images were acquired using an
inverted ﬂuorescent microscope Zeiss Axiovert 200M (Carl
Zeiss, Thornwood, NY, USA).
Quantitative real-time PCR
For mRNA quantiﬁcation, total RNA was extracted using the
RNAqueous kit and the cDNA was synthesized 1mg of total
RNA using High Capacity RNA-to-cDNA kit (Applied
Biosystems, Foster City, CA, USA) according to the manu-
facturer’s protocol. Quantitative real-time PCR was performed
using speciﬁc primers for GAPDH (Mm99999915_g1), IL-6
(Mm00446190_m1), TNF-a (Mm00443258_m1), IL-10
(Mm00439616_m1) and IL-1b (Mm00434228_m1) in a 7500
Real-Time PCR System (Applied Biosystems). Thermocycling
conditions consisted of an initial denaturation of 20s at 951C,
followed by 60 cycles of 951C for 30s and 601C for 30s. The
values obtained for the target gene expression were normalized
to GAPDH and quantiﬁed relative to the expression in
control samples. For the calculation of relative quantiﬁcation,
the 2
 DDCT formula was used, where  DDCT¼(CT,target–
CT,GAPDH) experimental sample (CT,target CT,GAPDH) con-
trol sample.
FACS analysis for immune cell populations
Immune cell populations in the whole blood, spleen and tumor
were analyzed by FACS analysis. One hundred microliters of
whole blood was collected using a hematocrit capillary tube
and blocked with Fc block (eBioscience, San Diego, CA, USA)
to reduce nonspeciﬁc antibody binding for 3min at room
temperature. Cells were then incubated in the dark with 10ml
of the appropriate ﬂuorochrome-conjugated antibodies from
eBioscience—T cells (anti-CD3-FITC, 1:25), B cells (anti-
CD19-PE, 1:25) and NK cells (anti-CD49-APC, 1:50) for
20min at 41C. Cells were washed with 500ml of FACS buffer
containing 0.02% sodium azide and 2% FBS in PBS. The red
blood cells were lysed for 5min with FACS lysis buffer (BD
Bioscience, Franklin Lakes, NJ, USA) at room temperature,
and then re-washed with FACS buffer. Finally, each sample
was ﬁxed with 1% paraformaldehyde until further analysis.
Flow cytometry analysis was performed on the FACSCalibur
system (BD Biosciences, Franklin Lakes, NJ, USA). Control
samples were matched for each ﬂuorochrome. Data were
analyzed using the CellQuest software (Becton Dickinson,
Franklin Lakes, NJ, USA). For immune cell population
analysis in the spleens and tumor, tissues were disrupted by
forcing them through 70-mm cell strainer into 10ml of cold
PBS using a rubber-tipped syringe plunger. The cell suspen-
sions were then centrifuged at 1500r.p.m. for 10min and the
supernatants were discarded. The cells were resuspended in
3ml ACK lysing buffer (Lonza, Walkersville, MD, USA) for
3min and the debris was sedimented by centrifuging at
1500r.p.m. for 10min. Cell concentrations were determined
by hemocytometer counting using Trypan blue dye exclusion,
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6 cells per ml. Single-cell suspen-
sions were stained with the following ﬂuorochrome-conjugated
antibodies from BD Biosciences: B cells (anti-B220-APC,
1:100), T cells (anti-CD3-FITC, 1:400), NK cells (anti-CD49-
APC, 1:50) and cytotoxic T cells (anti-CD8-FITC, 1:100).
Flow cytometry and data analysis was carried out as
mentioned above in the blood.
Statistical analysis
The data were analyzed using the GraphPad Prism 4 ver. 4.03
software (La Jolla, CA, USA). Data are presented as
means±s.d. The homogeneity of variances was assessed using
the Bartlett test in tumor incidence test. The differences in all
data were assessed by one-way analysis of variance. When the
P-value in the analysis of variance test indicated statistical
signiﬁcance, the differences were assessed by the Dunnett’s test.
Av a l u eo fPo0.05 was considered to be statistically signiﬁcant.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This work was supported by the Korea Research Foundation
Grant (MRC, R13-2008-001-00000-00) and the National R&D
Program for Cancer Control, Ministry for Health, Welfare and
Family affairs, Republic of Korea (0920080). D Yoon was
partially from National Research Foundation of Korea (2009-
0093824, 2010-0019306) and D Yu from KRIBB Research
Initiative Program Grant. We thank Dr Howard P Glauert
(University of Kentucky) who provided invaluable assistance
with English legal manuscripts.
References
Araki S, Omorin Y, Lyn D, Singh RK, Meinbach DM, Sandman Y
et al. (2007). Interleukin-8 is a molecular determinant of androgen
independence and progression in prostate cancer. Cancer Res 67:
6854–6862.
Ban JO, Oh JH, Hwang BY, Moon DC, Jeong HS, Lee S et al. (2009).
Inﬂexinol inhibits colon cancer cell growth through inhibition of
nuclear factor-kappaB activity via direct interaction with p50. Mol
Cancer Ther 8: 1613–1624.
Baud V, Karin M. (2009). Is NF-kappaB a good target for cancer
therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33–40.
Bollrath J, Greten FR. (2009). IKK/NF-kappaB and STAT3 path-
ways: central signaling hubs in inﬂammation-mediated tumor
promotion and metastasis. EMBO Rep 10: 1314–1319.
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y,
Pestell RG, Albanese C et al. (1999). Stat3 as an oncogene. Cell
98: 295–303.
Cacev T, Radosevic S, Krizanac S, Kapitanovic S. (2008). Inﬂuence of
interleukin-8 and interleukin-10 on sporadic colon cancer develop-
ment and progression. Carcinogenesis 29: 1572–1580.
Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P
et al. (2008). IL-32, a novel proinﬂammatory cytokine in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 178:
894–901.
Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J et al.
(2004). Disruption of Stat3 reveals a critical role in both the
initiation and the promotion stages of epithelial carcinogenesis.
J Clin Invest 114: 720–728.
Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E et al.
(2009). Identiﬁcation of the most active interleukin-32 isoform.
Immunology 126: 535–542.
Choi J, Bae S, Hong J, Ryoo S, Jhun H, Hong K et al. (2010).
Paradoxical effects of constitutive human IL-32gamma in transgenic
mice during experimental colitis. Proc Natl Acad Sci USA 107:
21082–21086.
Choi KC, Jung MG, Lee YH, Yoon JC, Kwon SH,
Knag HB et al. (2002). Epigallocatechin-3-gallate, a histone
acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte
transformation via suppression of RelA acetylation. Cancer Res 69:
583–592.
Dahl CA, Schall RP, He HL, Cairns JS. (1992). Identiﬁcation of a
novel gene expressed in activated natural killer cells and T cells.
J Immunol 148: 597–603.
Dinarello CA, Kim SH. (2006). A novel cytokine with a possible role
in disease. Ann Rheum Dis 65: iii61–iii64.
Fujimoto J, Aoki I, Toyoki H, Khatun S, Tamaya T. (2002). Clinical
implications of expression of ETS-1 related to angiogenesis in
uterine cervical cancer. Ann Oncol 13: 1598–1604.
Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S et al.
(2006). Involvement of IL-32 in activation-induced cell death in T
cells. Int Immunol 18: 233–240.
Grivennikov SI, Karin M. (2010). STAT3 and NF-kappaB collabora-
tion and crosstalk in cancer. Cytokine Growth Factor Rev 21: 11–19.
Groscurth P, Diener S, Stahel R, Jost L, Kagi D, Hengartner H.
(1990). Morphologic analysis of human lymphokine-activated killer
(LAK) cells. Int J Cancer 45: 694–704.
Hardwick JC, van den Brink GR, Offerhaus GJ, van Deventer SJ,
Peppelenbosch MP. (2001). NF-kappaB, p38 MAPK and JNK are
highly expressed and active in the stroma of human colonic
adenomatous polyps. Oncogene 20: 819–827.
Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y
et al. (2004). Potent antitumor activity of interleukin-27. Cancer Res
64: 1152–1156.
Hou T, Ray S, Lee C, Brasier AR. (2008). The STAT3 NH2-terminal
domain stabilizes enhanceosome assembly by interacting with the
p300 bromodomain. J Biol Chem 283: 30725–30734.
Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. (1996).
Interleukin 10 suppresses tumor growth and metastasis of human
melanoma cells: potential inhibition of angiogenesis. Clin Cancer
Res 2: 1969–1979.
Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. (2001). Over-
expression of interleukin-6 in human basal cell carcinoma cell lines
increases anti-apoptotic activity and tumorigenic potency. Oncogene
20: 198–208.
Jenkins BJ, Roberts AW, Najdovska M, Grail D, Ernst M. (2005). The
threshold of 130-dependent STAT3 signaling is critical for normal
regulation of hematopoiesis. Blood 105: 3512–3520.
Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS et al. (2009).
A proinﬂammatory cytokine interleukin-32b promotes the produc-
tion of an anti-inﬂammatory cytokine interleukin-10. Immunology
128: e532–e540.
Karin M, Cao Y, Greten FR, Li ZW. (2002). NF-kappaB in
cancer: from innocent bystander to major culprit. Nat Rev Cancer
2: 301–310.
Kim KH, Shim JH, Seo EH, Cho MC, Kang JW, Kim SH et al. (2008).
Interleukin-32 monoclonal antibodies for immunohistochemistry,
Western blotting, and ELISA. J Immunol Methods 333: 38–50.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. (2005). IL-32: a
cytokine and inducer of TNFalpha. Immunity 22: 131–142.
Kundu N, Fulton AM. (1997). Interleukin-10 inhibits tumor
metastasis, downregulates MHC class I, and enhances NK lysis.
Cell Immunol 180: 55–61.
Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z et al. (2009).
Persistently activated Stat3 maintains constitutive NF-kappaB
activity in tumors. Cancer cell 15: 283–293.
IL-32c inhibits cancer cell growth
JH Oh et al
3358
OncogeneLee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. (1998).
Interleukin 2 expression by tumor cells alters both the
immune response and the tumor microenvironment. Cancer Res
58: 1478–1485.
Lee S, Kim S, Bae S, Choi J, Hong J, Ryoo S et al. (2010). Interleukin-
32 gamma speciﬁc monoclonal antibody and developing IL-32
speciﬁc ELISA. Hybridoma 29: 501–509.
Levy DE, Darnell Jr JE. (2002). Stats: transcriptional control and
biological impact. Nat Rev Mol Cell Biol 3: 651–662.
Lin WW, Karin M. (2007). A cytokine-mediated link between
innate immunity, inﬂammation and cancer. J Clin Invest 117:
1175–1183.
Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G et al.
(2001). Nuclear factor-kappa B is upregulated in colorectal cancer.
Surgery 130: 363–369.
Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L et al. (2004).
Prognostic factors in resected stage I non-small-cell lung cancer: a
multivariate analysis of six molecular markers. J Clin Oncol 22:
4575–4583.
Ma X, Reynolds SL, Baker BJ, Li X, Benveniste EN, Qin H. (2010).
IL-17 enhancement of the IL-6 signaling cascade in astrocytes.
J Immunol 184: 4898–4906.
Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related
inﬂammation. Nature 454: 436–444.
Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA,
Deeg HJ. (2008). Dysregulation of IL-32 in myelodysplastic
syndrome and chronic myelomonocytic leukemia modulates
apoptosis and impairs NK function. Proc Natl Acad Sci USA 105:
2865–2870.
Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A. (2000).
Human NK-cell receptors. Immunol Today 21: 420–422.
Naugler WE, Karin M. (2008). NF-kappaB and cancer-identifying
targets and mechanisms. Curr Opin Genet Dev 18: 19–26.
Nishida A, Andoh A, Inatomi O, Fujiyama Y. (2009). Interleukin-32
expression in the pancreas. J Biol Chem 284: 17868–17876.
Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF, Dinarello
CA. (2009). IL-32-dependent effects of IL-1beta on endothelial cell
functions. Proc Natl Acad Sci USA 106: 3883–3888.
Ray S, Lee C, Hou T, Boldogh I, Brasier AR. (2008). Requirement of
histone deacetylase1 (HDAC1) in signal transducer and activator of
transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic
Acids Res 36: 4510–4520.
Schottelius AJ, Mayo MW, Sartor RB, Baldwin Jr AS. (1999).
Interleukin-10 signaling blocks inhibitor of kappaB kinase
activity and nuclear factor kappaB DNA binding. J Biol Chem
274: 31868–31874.
Seo EH, Kang J, Kim KH, Cho MC, Lee S, Kim HJ et al. (2008).
Detection of expressed IL-32 in human stomach cancer using
ELISA and immunostaining. J Microbiol Biotechnol 18: 1606–1612.
Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW,
Chatta G et al. (2006). Intratumoral cytokines/chemokines/growth
factors and tumor inﬁltrating dendritic cells: friends or enemies?
Cancer Metast Rev 25: 333–356.
Son DJ, Park MH, Chae SJ, Moon SO, Lee JW, Song HS et al. (2007).
Inhibitory effect of snake venom toxin from Vipera lebetina
turanica on hormone-refractory human prostate cancer cell growth:
induction of apoptosis through inactivation of nuclear factor
kappaB. Mol Cancer Ther 6: 675–683.
Sorrentino C, Di Carlo E. (2009). Expression of IL-32 in human lung
cancer is related to the histotype and metastatic phenotype. Am J
Respir Crit Care Med 180: 769–779.
Yu H, Pardoll D, Jove R. (2009). STATs in cancer inﬂammation and
immunity: a leading role for STAT3. Nat Rev Cancer 9: 798–809.
Wang AG, Moon HB, Lee MR, Hwang CY, Kwon KS, Yu SL et al.
(2005). Gender-dependent hepatic alterations in H-ras 12V trans-
genic mice. J Hepatol 43: 836–844.
Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV.
(2003). IL-6 induces NF-kappa B activation in the intestinal
epithelia. J Immunol 171: 3194–3201.
Westbrook AM, Wei B, Braun J, Schiestl RH. (2009). Intestinal
mucosal inﬂammation leads to systemic genotoxicity in mice.
Cancer Res 69: 4827–4834.
Zhang F, Suares G, Sha J, Sierra JC, Peterson JW, Chopra AK.
(2009). Phospholipase A2-activating protein (PLAA) enhances
cisplatin-induced apoptosis in HeLa cells. Cell signal 21: 1085–1099.
Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z et al.
(1996). Interleukin-10 inhibits tumor metastasis through an NK cell-
dependent mechanism. J Exp Med 184: 579–584.
ThisworkislicensedundertheCreativeCommons
Attribution-NonCommercial-Share Alike 3.0
Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
IL-32c inhibits cancer cell growth
JH Oh et al
3359
Oncogene